CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: March 17, 2020
Result type: Reports
Project Number: SR0626-000
Product Line: Reimbursement Review

Generic Name: glucagon

Brand Name: Baqsimi

Manufacturer: Eli Lilly Canada Inc.

Therapeutic Area: Severe hypoglycemic reactions

Indications: Severe hypoglycemic reactions

Manufacturer Requested Reimbursement Criteria1: For the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates.

Submission Type: Initial

Project Status: Complete

Companion Diagnostics: No

Date Recommendation Issued: January 22, 2020

Recommendation Type: Reimburse with clinical criteria and/or conditions

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedJune 25, 2019
Patient group input closedAugust 15, 2019

- Patient input submission received from Diabetes Canada and Type 1 Together/Ensemble

Patient input summary sent for review to patient input groupsSeptember 12, 2019
Patient group comments on input summary closedSeptember 19, 2019

- Patient input summary feedback received

Submission receivedJuly 24, 2019
Submission acceptedAugust 08, 2019
Review initiatedAugust 09, 2019
Draft CADTH review report(s) sent to sponsorOctober 24, 2019
Comments from sponsor on draft CADTH review report(s) receivedNovember 04, 2019
CADTH review team's comments on draft CADTH review report(s) sent to sponsorNovember 29, 2019
Canadian Drug Expert Committee (CDEC) meetingDecember 11, 2019
CDEC recommendation sent to sponsor and drug plansDecember 24, 2019
CDEC Final Recommendation & CADTH review report(s) issued to sponsor and drug plansJanuary 22, 2020
CDEC Final Recommendation postedJanuary 24, 2020
Redaction requests from sponsor on draft CADTH review report(s) receivedFebruary 05, 2020
Redacted CADTH review report(s) sent to sponsor and drug plansFebruary 18, 2020
Validation of redacted CADTH review report(s) receivedFebruary 25, 2020
Final CADTH review report(s) postedMarch 09, 2020